Tazeen Ahmad

Tazeen Ahmad Recent News

BofA Initiates Praxis Precision Medical At Buy
Praxis Precision Medicines Inc’s (NASDAQ: PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities.
Why BofA Is Turning Bullish On Prelude Therapeutics
Prelude Therapeutics Inc’s (NASDAQ: PRLD) share price represents “a particularly attractive buying opportunity,” and the stock has catalysts in the back half of the year, according to BofA Securities.
Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know
A BofA Securities analyst is turning bullish on shares of Ultragenyx Pharmaceuticals (NASDAQ: RARE). Here's why.  The Ultragenyx Analyst: Tazeen Ahmad upgraded Ultragenyx from Neutral to Buy with a $162 price target. 
Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst
Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc.
7 High-Risk Stocks For Market Gamblers
Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues.
Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca
7 Stocks To Buy Under $5
BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex
GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year
Analysts: Roche Partnership Derisks Sarepta Investor Concerns
Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially
Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Analysts Initiate Bullish Coverage Of Prevail Therapeutics
Sell-Side Slashes DBV Tech Price Targets After Withdrawal Of BLA For Peanut Allergy Immunotherapy
Bank Of America Bullish On GW Pharma, Expects Growth In Epidiolex Sales
Zogenix Has $3.4B Opportunity With Pediatric Epilepsy Asset, BofA Says In Bullish Initiation
BofA Revives Myokardia With New Buy Rating
GW Pharmaceuticals' FDA Win Reinforces BofA's Bullish Thesis
Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating
Four Reasons Behind BofA's Bullish Restorbio Initiation
Acadia's Valuation Looks Pretty Attractive Right Now: Bank Of America Upgrades To Buy
Theravance Just Lost Its Catalyst